The United States market has experienced a 1.5% increase over the last week and a substantial 26% rise over the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate robust innovation and adaptability to capitalize on these favorable conditions.
Top 10 High Growth Tech Companies In The United States
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: LightPath Technologies, Inc. is a company that designs, develops, manufactures, and distributes optical systems and assemblies in the United States with a market capitalization of $739.54 million.
Operations: LightPath Technologies focuses on the design, development, manufacturing, and distribution of optical systems and assemblies.
LightPath Technologies has demonstrated a robust annual revenue growth of 36.2%, significantly outpacing the broader U.S. market’s average of 11.6%. This growth is underpinned by strategic expansions like the recent GSA Multiple Award Schedule contract, enhancing its governmental reach, and the appointment of Doug Schoen, which strengthens its leadership in global sales with his extensive aerospace and defense industry experience. Despite current unprofitability and substantial shareholder dilution over the past year, LightPath is poised for profitability within three years with an expected earnings surge of 122.64% annually. These developments suggest a potentially bright future as it navigates towards operational profitability while expanding its technological footprint in high-demand sectors.
LPTH Earnings and Revenue Growth as at May 2026
Simply Wall St Growth Rating: ★★★★★☆
Overview: Intellia Therapeutics, Inc. is a clinical-stage genome editing company dedicated to developing potentially curative therapeutics using CRISPR/Cas9-based technologies, with a market cap of $2.01 billion.
Operations: Intellia Therapeutics focuses on developing therapeutics using CRISPR/Cas9 technology. The company is in the clinical stage, indicating that its primary activities involve research and development rather than generating revenue from product sales.
Intellia Therapeutics, amid substantial shareholder dilution, reported a narrowing net loss from $114.33 million to $96.23 million year-over-year for Q1 2026, reflecting tighter cost management and strategic R&D investments which totaled $180 million in recent equity offerings aimed at advancing CRISPR technologies. The firm’s recent HAELO trial success with lonvo-z showcased a significant reduction in hereditary angioedema attacks, positioning it potentially as the first one-time gene-editing treatment in this category. Despite current unprofitability, Intellia’s aggressive pursuit of innovative treatments underscores its potential pivotal role in transforming therapeutic standards and patient outcomes in genetic diseases.
NTLA Revenue and Expenses Breakdown as at May 2026
Simply Wall St Growth Rating: ★★★★★★
Overview: AppLovin Corporation offers comprehensive AI-driven advertising solutions globally, with a market cap of $160.72 billion.
Operations: The company generates revenue primarily through its advertising segment, which brought in $6.16 billion.
AppLovin’s recent performance underscores its robust position in the tech sector, with Q1 2026 sales soaring to $1.84 billion from $1.16 billion year-over-year, and net income more than doubling to $1.21 billion. This financial upswing is complemented by strategic share repurchases, with 2.17 million shares bought back in the first quarter alone, emphasizing confidence in its operational stability and future growth prospects. Furthermore, the company’s aggressive R&D focus not only fuels innovation but also aligns with industry shifts towards advanced software solutions, ensuring AppLovin remains at the forefront of technological advancements and market demands.
APP Revenue and Expenses Breakdown as at May 2026
Key Takeaways
Ready For A Different Approach?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LPTHNTLA and APP.
Leave a comment